基石藥業(02616.HK)抗PD-L1抗體完全緩解率達33.3%
基石藥業-B(02616.HK)公布,公司於2019年美國血液學會年會上,以海報展示形式發表了S1001-201 研究的最新數據。CS1001-201是一項旨在評價CS1001單藥治療復發或難治性結外自然殺傷細胞的單臂、多中心II期臨床研究。
基石藥業首席醫學官楊建新指,CS1001-201是全球範圍內首個針對ENKTL的抗PD-L1 抗體臨床研究。研究顯示,相比在自體移植前獲得部分緩解的患者,獲得完全緩解的患者可以顯著延長生存期、改善預後。最新研究數據顯示,CS1001的完全緩解率為33.3%且緩解可持續,同時客觀緩解率為43.3%,一年總生存率為72.4%,數據相比現有治療選項是一個巨大的突破,並將可能為後續造血幹細胞移植創造良好條件。 ~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.